CELL LINES
Contributor Information
- Name Anne Lykkesfeldt
- Institute Danish Cancer Society, Denmark
- Primary citation Lykkesfeldt et al. 1995. Int J Cancer. 61(4):529-534. PMID: 7759159.
Tool Details
- Tool name: MCF7/182R-6 Cell Line
- Alternate names: MCF-7/182R-6
- Tool type: Cell Lines
- Tool sub-type: Continuous
- Parental cell line: MCF7 S0.5
- Organism: Human
- Tissue: Breast
- Gender: Female
- Cancer type: Breast cancer
- Disease: Cancer
- Model: Tumour line
- Conditional: Yes
- Application: Investigation of molecular changes
-
Description: The MCF7/182R-6 cell line is a breast cancer cell line resistant to fulvestrant (Faslodex).
The MCF7/182R-6 cell line is a human breast cancer cell line established from a clone of MCF7/S0.5 cells surviving long term growth with the pure steroidal antiestrogen ICI 182,780 (fulvestrant) in 100 nM concentration. The cellular classification is epithelial, and their shape is polygonal.
MCF7/182R-6 cells express oestrogen receptor alpha and do not express progesterone receptor.
Treatment with the steroidal antioestrogen fulvestrant has proven effective upon progression on tamoxifen therapy and is now approved for second-line treatment after tamoxifen or aromatase inhibitors. As for tamoxifen treatment of advanced breast cancer, resistance will inevitably occur also for fulvestrant. Clarification of the molecular changes associated with the resistant growth is needed to find targeted treatments to resistant tumour cells and treatments that can inhibit or delay the emergence of resistance. - Research area: Cancer; Drug development
- Production details: The MCF7/182R-6 cell line has been established from a clone of MCF7/S0.5 cells surviving long term growth with the pure steroidal antiestrogen ICI 182,780 in 100 nM concentration, see Lykkesfeldt et al (1995). The MCF7/182R-6 cells are grown in the presence of fulvestrant.
- Cellosaurus ID: CVCL_W536
- For Research Use Only
Target Details
- Target: Oestrogen receptor
Application Details
- Application: Investigation of molecular changes
- Application notes: Upon withdrawal of fulvestrant, the resistant phenotype is stable and the cells express ER alpha, although at a reduced level. The MCF7/182R-6 cells do not express progesterone receptor. The MCF7/182R-6 cells express increased level of EGFR, phosphorylated EGFR and phosphorylated ErbB3 and reduced level of ErbB4 compared to the parental MCF7/S0.5 cells. Passage 421 (AL2533, AL2536) In mice, estrogen supplementation is required for formation of tumours, and treatment with ICI 182,780 inhibits tumour growth. This model is considered an in vitro model. The fulvestrant resistant cells have progressed towards reduced estrogen dependence and unpublished in vivo experiments indicate that fulvestrant resistant xenografts may be established by inoculation of MCF-7/182R-6 cells in animals treated with estrogen and then treatment with fulvestrant until regrowth of the tumor.
Handling
- Format: Frozen
- Growth medium: Phenol red free DMEM/F12 (1:1) supplemented with 1% FCS, Glutamax 2,5 mM and 6 ng/ml insulin. Supplemented with 100nM fulvestrant to maintain resistance.
- Temperature: 37° C
- Atmosphere: 5% CO2
- Storage conditions: Liquid Nitrogen
- Shipping conditions: Dry ice
- Mycoplasma free: Yes
- Biosafety level: 1
Documentation
References
- • Thrane et al. 2014. Oncogene. 34(32):4199-4210. PMID: 25362855.
- • Sonne-Hansen et al. 2010. Breast Cancer Res Treat. 121(3):601-613. PMID: 19697122.
- • Frogne et al. 2008. Breast Cancer Res Treat. 114(2):263-275. PMID: 18409071.
- • Frankel et al. 2006. Breast Cancer Res Treat. 104(2):165-179. PMID: 17061041.
- • Frogne et al. 2005. Endocr Relat Cancer. 12(3):599-614. PMID: 16172194.
- • Nabha et al. 2005. Oncogene. 24(19):3166-3176. PMID: 15735693.
- • Lykkesfeldt et al. 1995. Int J Cancer. 61(4):529-534. PMID: 7759159.
.svg)
Unit size: 
.svg)
.svg)
